CVSA
Covista Inc.
CVSA's fundamentals are strong: it turned 18% of its revenue into free cash flow and revenue grew 9.3%. At 16x earnings, it's trading below its usual 19x. Analysts expect strong earnings growth.
CVSA Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Healthy | |
| Healthy |
CVSA's revenue, profitability, cash flow and balance sheet are all currently healthy.
CVSA PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 6x | $44.17 | -63% |
| Forward | 13x | $119 | — |
| Current | 16x | $119 | — |
| Fair | 18x | $135 | +14% |
| Expensive | 24x | $173 | +46% |
Historical ranges are pointers, not guarantees.
CVSA's PE is in its fair range at 16x. If earnings grow as analysts expect, today's price would be 13x next year's earnings, in its cheap range.
CVSA Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Growth | |
| Improving | |
| Limited | |
| Moderate |
Analysts expect earnings and revenue growth for CVSA, with profitability improving.
CVSA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $9.18 | +25% |
| Q3 2026 | $7.32 | +9.7% |
| Q2 2026 | $7.04 | +14% |
| Q1 2026 | $6.41 | +7.2% |
| Q4 2025 | $6.80 | +28% |
| Q3 2025 | $6.67 | +54% |
| Q2 2025 | $6.18 | +82% |
| Q1 2025 | $5.98 | +127% |
| Q4 2024 | $5.32 | +96% |
CVSA's earnings per share have climbed steadily: $7.32 over the past year, up 9.7% from the year before, and higher year over year for 11 quarters in a row.
CVSA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $511.5M | +11% |
| Q2 2026 | $501.4M | +9.7% |
| Q1 2026 | $487M | +4.5% |
| Q4 2025 | $503.4M | +12% |
| Q3 2025 | $462.3M | +11% |
| Q2 2025 | $457.1M | +12% |
| Q1 2025 | $466.1M | +13% |
| Q4 2024 | $447.7M | +14% |
CVSA's revenue has grown year over year for 15 quarters in a row: $512M last quarter, up 11% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 19% | +0.7 points |
| Q2 2026 | 19% | +2.2 points |
| Q1 2026 | 19% | -0.7 points |
| Q4 2025 | 22% | -1.1 points |
| Q3 2025 | 18% | +1.7 points |
| Q2 2025 | 17% | +0.1 points |
| Q1 2025 | 19% | +4.5 points |
| Q4 2024 | 23% | +8.3 points |
CVSA's operating margin was 19% last quarter, up 0.7 points from the same quarter a year ago.
CVSA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $76.4M | -33% |
| Q2 2026 | $97.1M | +139% |
| Q1 2026 | $165.9M | -16% |
| Q4 2025 | $15.1M | +$44.8M |
| Q3 2025 | $114.5M | +45% |
| Q2 2025 | $40.7M | -6.8% |
| Q1 2025 | $197.7M | +40% |
| Q4 2024 | -$29.7M | -$7.3M |
CVSA generated $355M in free cash flow over the past year, up 9.7% from the year before.
CVSA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -3.2% | -1.1M shares |
| 1 year | -6.7% | -2.5M shares |
| 3 years | -18% | -7.6M shares |
| 5 years | -30% | -15.1M shares |
| Available history | -36% | -19.5M shares |
CVSA has 35M diluted shares, down 6.7% from a year ago, with $313M in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | $81M |
| Q2 2026 | — |
| Q1 2026 | $67.5M |
| Q4 2025 | $164.8M |
| Q3 2025 | $7.6M |
| Q2 2025 | $66.7M |
| Q1 2025 | $72.4M |
| Q4 2024 | $40.9M |
CVSA spent $313M buying back its own shares over the past year, up 67% from the year before.
CVSA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.6x | Very low |
| Q2 2026 | 0.6x | Very low |
| Q1 2026 | 0.8x | Very low |
| Q4 2025 | 1.1x | Healthy |
| Q3 2025 | 0.7x | Very low |
| Q2 2025 | 0.9x | Very low |
| Q1 2025 | 0.9x | Very low |
| Q4 2024 | 1.2x | Healthy |
CVSA's net debt is less than a year of its operating earnings (EBITDA).
CVSA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 47.3 | Neutral |
| Stochastic | 24.4 | Neutral |
CVSA's weekly RSI is 47 (neutral) and its Stochastic is 24 (neutral).
CVSA PE vs Consumer Cyclical Sector
| Metric | CVSA | Sector median | Relative |
|---|---|---|---|
| PE | 16x | 18x | 9.8% below |
| PE % | 33 | 47 | 14 pts below |
CVSA is trading at 16x earnings, in line with the Consumer Cyclical sector's median of 18x.
CVSA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $123.5 | 3.6% below |
| 20 week MA | $126.4 | 5.8% below |
| 50 week MA | $117.5 | 1.3% above |
| 100 week MA | $116.5 | 2.2% above |
| 200 week MA | $85.9 | 39% above |
CVSA has pulled back, but its long-term trend is still up: it's below its 8- and 20-week averages, but 39% above its 200-week average.
CVSA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $35.0 | $34.4 | -1.8% |
| 2021 | $34.4 | $30.0 | -13% |
| 2022 | $30.0 | $36.2 | +20% |
| 2023 | $36.2 | $59.0 | +63% |
| 2024 | $59.0 | $90.9 | +54% |
| 2025 | $90.9 | $104.7 | +15% |
| 2026 YTD | $104.7 | $119.0 | +14% |
CVSA has finished higher in four of the last six years, two of them by more than 50%. It's up 14% so far in 2026.